Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares by mparnell | Nov 19, 2018 | Portfolio News
Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine by mparnell | Nov 18, 2018 | Portfolio News
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company by mparnell | Nov 15, 2018 | Portfolio News
Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights by mparnell | Nov 13, 2018 | Portfolio News
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans by mparnell | Nov 12, 2018 | Portfolio News